(Q41589680)

4 October 2017

1 reference

title

Promotion of endogenous remyelination in multiple sclerosis (English)

1 reference

4 October 2017

C F Lucchinetti

1

1 reference

4 October 2017

J H Noseworthy

series ordinal

2

1 reference

4 October 2017

M Rodriguez

series ordinal

3

1 reference

4 October 2017

1 April 1997

1 reference

Multiple Sclerosis Journal

4 October 2017

1 reference

4 October 2017

3

1 reference

4 October 2017

2

1 reference

4 October 2017

71-75

1 reference

Electron microscopic features of multiple sclerosis lesions

4 October 2017

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Oligodendrocyte injury is an early event in lesions of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Ultrastructure of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Oligodendrocytes in the early course of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Demyelination of the superior cerebellar peduncle in the mouse induced by cuprizone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

The T lymphocyte in experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Glycolipids and transmembrane signaling in oligodendroglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Immunosuppression promotes CNS remyelination in chronic virus‐induced demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300202

10.1177/135245859700300202

21 January 2018

Identifiers

DOI

0 references

1 reference